Milestone Scientific Partners with RedOne Medical to Distribute the CompuFlo Epidural System to VA and DoD Medical Facilities Worldwide

LIVINGSTON, NJ / ACCESSWIRE / December 11, 2019 / Milestone Scientific Inc. (NYSE American:MLSS), a leading developer of computerized drug instruments that provide painless and precise injections, today announced that it has partnered with RedOne Medical, a leading medical device distributor and wholesaler serving the Department of Veterans Affairs (VA) medical centers and Department of Defense (DoD) hospitals, to distribute the CompuFlo™ Epidural System.

Charles Pollak, Founder and CEO of RedOne Medical, stated, "We are excited to partner with Milestone Scientific to improve healthcare outcomes for America's warfighter and veteran patients. This clinically proven technology is 99% effective in identifying the epidural space on the first attempt, 14% more successful in patients with high body mass index, and reduces procedure time by one minute. We are honored to support VA and DoD hospitals with this innovative healthcare solution."

Brent Johnston, President of Milestone Scientific, commented, "Partnering with RedOne will provide us access to all federal medical facilities worldwide and is just one of many strategic initiatives we will be implementing at Milestone Scientific in order to support the global rollout strategy of the CompuFlo Epidural System. We look forward to our future relationship with RedOne."

About RedOne Medical

RedOne Medical is a CVE-certified Service-Disabled Veteran-Owned Small Business (SDVOSB) located in Savannah, GA. Wholly owned and operated by a combat veteran, RedOne Medical is a leading medical device distributor and wholesaler serving the Department of Veterans Affairs (VA) medical centers and Department of Defense (DoD) hospitals. RedOne Medical donates a portion of profits to leading charities as part of its mission to support veterans, military families and their communities.

About Milestone Scientific Inc.

Milestone Scientific Inc. (MLSS) is a biomedical technology research and development company that patents, designs, develops and commercializes innovative diagnostic and therapeutic injection technologies and instruments for medical, dental, cosmetic and veterinary applications. Milestone's computer-controlled systems are designed to make injections precise, efficient, and virtually painless. Milestone's proprietary DPS Dynamic Pressure Sensing technology® is our technology platform that advances the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions for local anesthesia for subcutaneous drug delivery, with specific applications for cosmetic botulinum toxin injections, epidural space identification in regional anesthesia procedures and intra-articular joint injections. For more information please visit our website: www.milestonescientific.com.

Safe Harbor Statement

This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues, timing of regulatory approvals and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions, future business decisions and regulatory developments, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2018. The forward-looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.
**Contact:**
David Waldman or Natalya Rudman
Crescendo Communications, LLC
Email: mlss@crescendo-ir.com
Tel: 212-671-1020

**SOURCE:** Milestone Scientific Inc.

View source version on accesswire.com: